Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
16.35
+0.35 (2.19%)
Oct 30, 2025, 12:57 PM EDT - Market open
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 11 analysts that cover Cogent Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $22, which forecasts a 34.56% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $44.
Price Target: $22 (+34.56%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 4 | 5 | 6 | 6 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 9 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $30 → $44 | Buy | Maintains | $30 → $44 | +169.11% | Oct 21, 2025 |
| Stifel | Stifel | Hold Initiates $16 | Hold | Initiates | $16 | -2.14% | Oct 16, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +83.49% | Sep 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $17 → $20 | Strong Buy | Maintains | $17 → $20 | +22.32% | Aug 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $29 → $30 | Buy | Maintains | $29 → $30 | +83.49% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
33.80M
EPS This Year
-2.27
from -2.46
EPS Next Year
-1.91
from -2.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 119.5M | |||
| Avg | n/a | 33.8M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.95 | -1.03 | |||
| Avg | -2.27 | -1.91 | |||
| Low | -2.37 | -2.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.